IP Library Patent Application 14279045
Patent Application
App. No. 14/279,045

MICROPARTICLES FOR SELECTIVELY TARGETED HYPERTHERMIA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/279,045
Abstract

A microparticle composition(s) comprising nanomagnetic particles and a matrix, wherein said microparticle composition(s) have a least one of the following properties: (a) a VAR of at least about 1 Watts/cm3 subject to appropriate field conditions; (b) a density of about 2.7 or less: or (c) a size of about 100 nm to about 200 microns.

Claims (37)

1 . A micro particle composition comprising nanomagnetic particles distributed within a matrix, wherein the microparticles within the composition have a least one of the following properties: (a) a VAR of at least about 1 Watts/cm 3 under alternating magnetic field conditions suitable for use in a patient; (b) a density of about 2.7 or less; or (c) a size range of about 100 nm to about 200 microns.

2 . A microparticle composition comprising nanomagnetic particles distributed within a matrix, wherein up to 40% of the volume of each microparticle composition is occupied by the constituent magnetic nanoparticles and the microparticles within the composition have at least one of the following properties: (a) a VAR of at least about 10 Watts/cm 3 under alternating magentic field conditions suitable for use in a patient; (b) a density of about 2.7 or less; or (c) a size range of about 100 nm to 200 microns.

3 . A microparticle composition according to claim 2 wherein the volume fraction of nanomagnetic particles in the microparticles is less than 30% of the microparticle composition.

4 . A microparticle composition according to claim 2 wherein the volume fraction of nanomagnetic particles in the microparticles is less than 20% of the microparticle composition.

5 . A microparticle composition according to claim 2 wherein the volume fraction of nanomagnetic particles in the micro particles is less than 15% of the microparticle composition.

6 . A microparticle composition according to claim 2 wherein the volume fraction of nanomagnetic particles in the microparticles is less than 10% of the microparticle composition.

7 . A microparticle composition according to claim 2 wherein the volume fraction of nanomagnetic particles in the microparticles is less than 5% of the microparticle composition.

8 . A microparticle composition according to claim 1 wherein the microparticles within the composition have a density of about 2.7 or less.

9 . A microparticle composition according to claim 1 wherein the microparticles within the composition have a size of about 100 nm to about 200 microns.

10 . A microparticle composition according to claim 1 wherein the microparticles within the composition have a VAR of about 10 Watts/cm 3 under alternating magnetic field conditions suitable for use in a patient.

11 . A micro particle composition according to claim 1 wherein the alternating magnetic field is operated at a frequency in the range of about 50-300 kHz and field strength of about 60-120 Oe.

12 . A microparticle composition according to claim 1 wherein the alternating magnetic field is operated at a frequency in the range of about 100-200 kHz and field strength of about 60 Oe.

13 . A microparticle composition according to claim 11 wherein the alternating magnetic field is operated at a frequency in the range of about 100 kHz and 20 field strength of about 90 Oe.

14 . A microparticle composition according to claim 1 wherein the nanomagnetic particles distributed within the micro particles are superparamagnetic particles.

15 . A microparticle composition according to claim 14 wherein the superparamagnetic particles are either: (a) ferrites of general formula MO.Fe203 where M is a bivalent metal such as Fe, Co, Ni, Mn, Be, Mg, Ca, Ba, Sr, Cu, Zn, Pt or mixtures thereof, or (b) magnetoplumbite type oxides of the general formula MO.6Fe203 where M is a large bivalent ion, metallic iron, cobalt or nickel.

16 . A microparticle composition according to claim 15 wherein the superparamagnetic particles are free Fe, Ni, Cr or Co; oxides of Fe, Ni, Cr or Co; or mixtures of Fe, Ni, Cr or Co.

17 . A microparticle composition according to claim 15 wherein the superparamagnetic particles are prepared from iron oxide such as magnetite (Fe304) or maghemite (γ-Fe203) and have a size of less than 50 nm.

18 . A microparticle composition according to claim 16 wherein the superparamagnetic particles are maghemite nanoparticles.

19 . A microparticle composition according to claim 1 wherein the superparamagnetic particles have a size of between 1 nm and 40 nm.

20 . A microparticle composition according to claim 1 wherein the composition is prepared from materials suitable for use in a patient and the particles when delivered to a patient are and placed in an alternating magnetic field are capable of heating tissue in said patient.

21 . A microparticle composition according to claim 1 wherein the matrix in which the nanoparticles are distributed is a polymer matrix.

22 . A microparticle composition according claim 21 wherein the polymer matrix is suitable for use in human.

23 . A micro particle composition according to claim 21 wherein the polymer matrix is a biodegradable polymer matrix.

24 . A micro particle composition according to claim 23 wherein the polymer matrix biodegrades to after one to three months following introduction into a patient.

25 . A micro particle composition according to claim 1 wherein the micro particles in the composition are adapted for site specific delivery to or accumulation within a tissue in a patient.

26 . A microparticle composition according to claim 1 wherein the composition includes pharmaceutically acceptable carriers and or diluents.

27 . A micro particle composition according to claim 1 wherein the microparticles in the composition also include bioactive, chemical or radioactive agents that are capable of delivering a therapeutic effect to a patient.

28 . A method for heating a target site in a patient including the steps of:

(i) administering a microparticle composition according to claim 22 to a target site in a patient; and

(ii) exposing the target site to an alternating magnetic field, of a clinically acceptable frequency and strength,

wherein the combination of the alternating magnetic field with the micro particle composition induces heat within the target site.

29 . The method according to claim 28 wherein the microparticles are of a size and density that permits the transport of the microparticle composition to the capillary beds supplying the target site.

30 . The method according to claim 28 wherein the alternating magnetic field is operated at a frequency in the range of about 50-300 kHz and field strength of about 60-120 Oe.

31 . The method according to claim 30 wherein the alternating magentic field is operated at a frequency of about 100 kHz and a field strength of about 90 Oe.

32 . The use of a micro particle composition according to claim 1 in the manufacture of a medicament for the treatment of diseased tissue.

33 . A micro particle preparation comprising nanomagnetic particles distributed within a matrix, wherein the microparticles within the preparation have at least one of the following properties: (a) a VAR of at least about 1 Watts/cm 3 under alternating magnetic field conditions suitable for use in a patient; (b) a density of about 2.7 or less; or (c) a size range of about 100 nm to about 200 microns.

34 . The use of a micro particle preparation according to claim 33 in the manufacture of a medicament for the treatment of diseased tissue.

Assignments (1)
SECURITY INTEREST Recorded Nov 30, 2018
From: SIRTEX MEDICAL LIMITED
To: BANK OF CHINA LIMITED MACAU BRANCH
Reel/Frame 047691/0520 →